NYSE - Delayed Quote USD

Thermo Fisher Scientific Inc. (TMO)

573.60 +1.87 (+0.33%)
At close: April 26 at 4:00 PM EDT
573.31 -0.29 (-0.05%)
After hours: April 26 at 5:30 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
42,857,000.00
42,857,000.00
44,915,000.00
39,211,000.00
32,218,000.00
Cost of Revenue
25,295,000.00
25,757,000.00
25,944,000.00
19,573,000.00
16,214,000.00
Gross Profit
17,562,000.00
17,100,000.00
18,971,000.00
19,638,000.00
16,004,000.00
Operating Expense
10,244,000.00
9,782,000.00
10,464,000.00
9,413,000.00
8,111,000.00
Operating Income
7,318,000.00
7,318,000.00
8,507,000.00
10,225,000.00
7,893,000.00
Net Non Operating Interest Income Expense
-496,000.00
-496,000.00
-454,000.00
-493,000.00
-488,000.00
Other Income Expense
-524,000.00
-524,000.00
-218,000.00
-891,000.00
-175,000.00
Pretax Income
6,298,000.00
6,298,000.00
7,835,000.00
8,841,000.00
7,230,000.00
Tax Provision
284,000.00
284,000.00
703,000.00
1,109,000.00
850,000.00
Earnings from Equity Interest Net of Tax
-59,000.00
-59,000.00
-172,000.00
-4,000.00
-3,000.00
Net Income Common Stockholders
5,995,000.00
5,995,000.00
6,950,000.00
7,725,000.00
6,375,000.00
Diluted NI Available to Com Stockholders
5,995,000.00
5,995,000.00
6,950,000.00
7,725,000.00
6,375,000.00
Basic EPS
15.52
15.52
17.75
19.62
16.09
Diluted EPS
15.45
15.45
17.63
19.46
15.96
Basic Average Shares
386,000.00
386,000.00
392,000.00
394,000.00
396,000.00
Diluted Average Shares
388,000.00
388,000.00
394,000.00
397,000.00
399,000.00
Total Operating Income as Reported
6,859,000.00
6,859,000.00
8,393,000.00
10,028,000.00
7,794,000.00
Total Expenses
35,539,000.00
35,539,000.00
36,408,000.00
28,986,000.00
24,325,000.00
Net Income from Continuing & Discontinued Operation
5,995,000.00
5,995,000.00
6,950,000.00
7,725,000.00
6,375,000.00
Normalized Income
6,433,302.00
6,433,345.00
7,053,740.00
7,897,375.00
6,462,318.00
Interest Income
879,000.00
879,000.00
272,000.00
43,000.00
65,000.00
Interest Expense
1,375,000.00
1,375,000.00
726,000.00
536,000.00
553,000.00
Net Interest Income
-496,000.00
-496,000.00
-454,000.00
-493,000.00
-488,000.00
EBIT
7,673,000.00
7,673,000.00
8,561,000.00
9,377,000.00
7,783,000.00
EBITDA
11,079,000.00
11,079,000.00
11,942,000.00
11,969,000.00
10,108,000.00
Reconciled Cost of Revenue
24,227,000.00
25,757,000.00
25,944,000.00
19,573,000.00
16,214,000.00
Reconciled Depreciation
3,406,000.00
3,406,000.00
3,381,000.00
2,592,000.00
2,325,000.00
Net Income from Continuing Operation Net Minority Interest
5,995,000.00
5,995,000.00
6,950,000.00
7,725,000.00
6,375,000.00
Total Unusual Items Excluding Goodwill
-459,000.00
-459,000.00
-114,000.00
-197,000.00
-99,000.00
Total Unusual Items
-459,000.00
-459,000.00
-114,000.00
-197,000.00
-99,000.00
Normalized EBITDA
11,538,000.00
11,538,000.00
12,056,000.00
12,166,000.00
10,207,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-20,698.00
-20,655.00
-10,260.00
-24,625.00
-11,682.00
12/31/2020 - 3/17/1980

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DHR Danaher Corporation
246.58
+0.32%
 
MEDP Medpace Holdings, Inc.
395.93
+1.58%
 
DGX Quest Diagnostics Incorporated
134.26
-0.86%
 
ILMN Illumina, Inc.
122.28
+1.02%
 
LH Laboratory Corporation of America Holdings
198.40
+0.03%
 
IDXX IDEXX Laboratories, Inc.
499.30
+2.06%
 
A Agilent Technologies, Inc.
137.74
+1.00%
 
WAT Waters Corporation
311.30
+0.96%
 
CRL Charles River Laboratories International, Inc.
229.03
+0.54%
 
EXAS Exact Sciences Corporation
58.85
+0.10%